The aims of this systematic review were to: (1) critically appraise, synthesize and present the available evidence on the views and experiences of stakeholders on pharmacist prescribing and; (2) present the perceived facilitators and barriers for its global implementation.
Introduction
While prescribing has traditionally been restricted to medical practitioners (doctors and dentists), the rapid advancements in healthcare policies and practices have led to the introduction of models of nonmedical prescribing in several countries, with others exploring its potential [1, 2] . Nonmedical prescribing is most developed in the UK, with legislative changes enabling the implementation of supplementary prescribing (SP) in 2003 and independent prescribing (IP) in 2006, as described in Table 1 .
Implementation is most advanced in Scotland, and particularly for pharmacists, where approximately 40% of pharmacists in 2017 were either prescribers registered with the General Pharmaceutical Council or undertaking an approved training programme [7] . Developments in Scotland are supported by the policy driven approach of the Scottish Government, articulated in 2013 with the publication of Prescription for Excellence: a vision and action plan for the right pharmaceutical care through integrated partnerships and innovation [8] . This outlined the goal that "all patients, regardless of their age and setting of care, receive high quality pharmaceutical care from clinical pharmacist independent prescribers" [8] . The aspiration is that all patient-facing pharmacists will be clinical pharmacist independent prescribers by 2023. This commitment to developing the clinical prescribing role of pharmacists in all practice settings was reaffirmed in 2017 with publication by the government of Achieving Excellence in Pharmaceutical Care [7] . Details of other models of pharmacist prescribing which have been implemented in the USA, Canada and New Zealand are given in Table 2 , highlighting the diverse scope of prescribing rights.
There is increasing evidence of the effectiveness and safety of pharmacist prescribing. A recently published Cochrane review of 46 studies (37 337 participants) of prescribing by pharmacists (20 studies) and nurses (26 studies) compared to medical prescribing for a range of acute and chronic conditions included meta-analyses of surrogate Table 1 Characteristics of supplementary and independent prescribing in the UK [3, 4] Supplementary prescribing Independent prescribing Year of introduction in the UK 2003 UK 2006 Definition "A voluntary partnership between an independent prescriber (doctor or dentist) and a supplementary prescriber to implement an agreed patient-specific CMP with the patient's agreement" [5] "The prescribing by a practitioner (e.g. doctor, dentist, nurse, pharmacist) responsible and accountable for the assessment of patients with undiagnosed or diagnosed conditions and for decisions about the clinical management required, including prescribing" [6] clinical markers [13] . The review concluded that nonmedical prescribers, practising with varying but high levels of prescribing autonomy, in a range of settings, were as effective as usual care medical prescribers. Nonmedical prescribers recorded comparable outcomes for systolic blood pressure, glycated haemoglobin, low-density lipoprotein cholesterol, medication adherence and health-related quality of life.
There is also emerging evidence of safety with pharmacist prescribers in Scotland performing well in pilot studies of the UK Prescribing Safety Assessment [14] . This evidence of effectiveness has the potential to support pharmacist prescribing developments across the world. In addition, feedback from key stakeholder groups in terms of their views and experiences about pharmacists prescribing is vital to determine the possible factors influencing its implementation and thus inform the development and realization of such initiatives in other countries. Such stakeholders, are defined in the context of health and associated research by the Agency for Healthcare Research and Quality [15] as, "persons or groups that have a vested interest in a clinical decision and the evidence that supports that decision". Examples of health stakeholders include patients, clinicians, advocacy groups, and policymakers, all of whom have roles in developing, implementing, delivering, experiencing or evaluating nonmedical prescribing interventions.
The aim of this systematic review was to critically appraise, synthesize and present the available evidence on the views and experiences of stakeholders on pharmacist prescribing, including potential facilitators and barriers, regardless of implementation status.
Methods
A systematic review protocol was developed, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol (PRISMA-P) standards, and registered on International Prospective Register of Systematic Reviews (PROSPERO) at the Centre for Reviews and Dissemination in the UK (CRD42016048072) [16] .
Inclusion criteria
Studies reporting views and/or experiences of any stakeholder group (e.g. patients, general public, physicians, nurses, pharmacists) pertaining to pharmacist prescribing, irrespective of the stage of implementation (pre or post), model Table 2 Summary of pharmacist prescribing models globally
Country
Prescribing model Description USA CDTM Defined by the American College of Clinical Pharmacy as "a collaborative practice agreement between one or more physicians and pharmacists wherein qualified pharmacists working within the context of a defined protocol are permitted to assume professional responsibility for performing patient assessments; ordering drug therapy-related laboratory tests; administering drugs; and selecting, initiating, monitoring, continuing, and adjusting drug regimens" [9, 10] .
of prescribing (e.g. supplementary, independent or collaborative), with no date or language limit up to November 2017, were included in this systematic review. All peer-reviewed, primary research studies were included, while literature reviews, narrative reports and editorials were excluded. The inclusion process was performed by T.J. and reviewed by D.S.
Search strategy
The search string applied to Medline is given in Box 1; and adapted for Cumulative Index to Nursing and Allied Health Literature (CINAHL), International Pharmaceutical Abstracts (IPA), PsychArticles and Google Scholar. The reference lists of all identified articles in the full text screening were searched manually for potentially eligible studies meeting the review criteria.
Box 1
Search string applied to Medline (title, abstract, keywords, subject heading) ((view* OR perspective* OR perception* OR opinion* OR attitude* OR belief* OR thought* OR feel* OR impress* OR stance* OR viewpoint* OR standpoint* OR position* OR support* OR concern* OR confiden* OR expect*) OR (experience* OR satisf* OR reflect* OR react* OR content* OR understand* OR encounter* OR evaluat* OR feedback)) AND "pharmacist* prescrib*"
Assessment of methodological quality
Quality assessment was undertaken by two independent reviewers using the Mixed Methods Appraisal Tool (MMAT) [17] , which permits the appraisal of qualitative, quantitative and mixed methods studies. Consensus was reached through discussion or by a consultation with a third reviewer.
Data extraction
Data extraction was performed by two independent reviewers, with a third included if any disagreement occurs. Data items extracted were: stated aim/objective, phase of implementation (pre vs. post), country of focus, model of prescribing, stakeholder group, study design and key findings.
Data synthesis
Due to heterogeneity of phase of implementation, models of prescribing, study designs, and variability of data collection tools, a meta-analysis approach of quantitative findings was not possible. Hence, a narrative approach to data synthesis was applied. Pooling of qualitative research findings involved the aggregation or synthesis of findings to generate a set of statements that represented that aggregation, through assembling and categorizing findings based on similarity in meaning.
Results
The electronic search yielded 331 studies. Removal of duplicates resulted in 273 articles, 226 of which were excluded based on title, abstract, or full-text review. An additional 18 studies were identified from other sources (e.g. reference lists) resulting in 65 eligible studies for quality assessment and data extraction. The PRISMA flow diagram is provided in Figure 1 .
Quality of included studies
Most studies employed quantitative designs, largely questionnaire-based survey methodology (n = 41) , with fewer qualitative designs (n = 21) . The remaining three studies were sequential explanatory mixed methods studies all with survey followed by either focus group discussions [80, 81] or interviews [82] . Quality assessments given in Figure 2 highlight the largely robust and rigorous nature of the studies reviewed.
The key limitations of the survey studies were the lack of details around sampling strategies and the stages of questionnaire development, review and piloting. Only 14 studies had achieved the MMAT target response rate of 60% [19, 22-26, 29, 32, 36, 39, 40, 52, 54, 57] . Qualitative studies lacked details of approaches to ensuring data trustworthiness and the mixed methods studies provided limited information on integrating quantitative and qualitative data. However, all 65 studies had sufficient robustness and rigour to be included in the stages of data extraction and synthesis.
Characteristics and key findings of included studies
The extracted data are summarized in Tables 3, 4 and 5 for the  quantitative, qualitative and mixed methods studies  respectively. Of the 65 studies, 29 (45%) were conducted prior to the implementation of pharmacist prescribing in the country of study [18, 38-57, 74-79, 81, 82] , while the remaining 35 (54%) were conducted postimplementation [19-37, 58, 59, 61-73, 80] . Only one study explored views and experiences pre-and postregistration [60] .
Most of the included studies were conducted in the UK (n = 34, 52%) [21-31, 33-35, 37, 40-44, 59-69, 71, 73, 80] , followed by Australia (n = 13, 20%) [18, 45-48, 51, 54, 55, 74, 77, 79, 81, 82] , Canada (n = 6, 9%) [32, 36, 49, 58, 70, 76] , USA (n = 5, 8%) [19, 20, 38, 39, 72] , Nigeria (n = 4, 6%) [50, 52, 56, 78] , and one each for Ireland [53] , India [57] and New Zealand [75] .
The main stakeholder group studied was pharmacists (n = 27, 42%), including those registered as prescribers [22, 26, 29, 63, 67, 80] , nonprescribers [23, 24, 30, 32, 44-48, 51, 55, 56, 73, 74] , or mixed prescribers and nonprescribers [19, 20, 37, 58, 60, 66, 70] . Fewer studies investigated the perceptions of patients (n = 12, 19%) [18, 25, 27, 31, 34, 36, 38, 52, 54, 64, 68, 71] , doctors (n = 6, 9%) [21, 40, 42, 61, 75, 82] , the general public (n = 4, 6%) [28, 33, 49, 57] , nurses (n = 1, 2%) [43] or policymakers (n = 1, 2%) [76] . Fourteen studies reported multiple stakeholder perspectives [35, 39, 41, 50 While most studies (n = 41, 63%) provided a standardized or legislative definition of pharmacist prescribing, 24 (37%) did not [19, 21, 25, 30, 31, 36-38, 40-43, 46, 49, 50, 52-54, 57, 73, 77-80] .
For quantitative studies, the sample size ranged from 105 to 4158, with response rates of 6.4% to 87%. By contrast, qualitative studies included between eight and 82 participants. For mixed methods studies, the sample size in the quantitative element ranged from 15 to 179, with response rates of 15-100%, while the number of participants in the qualitative element ranged from eight to 10.
Stakeholders' views and experiences of pharmacist prescribing
The majority of both pre-and postimplementation studies included reported support for prescribing pharmacists. There were diverse views on the models and scope of prescribing which ranged from prescribing within an agreed clinical management plan (CMP), repeat prescribing for stabilized chronic conditions, and modifying treatment based on the results of laboratory tests ordered by themselves [56, 74, 81] . Many respondents also viewed IP as appropriate for pharmacists, noting that it will be safe and effective and improve patient access to medicines. They generally held the view that physicians would be in favour of pharmacist prescribing [51, 55] .
d. Doctors: Studies conducted preimplementation of pharmacist prescribing reported a range of views from doctors (n = 9). In one study conducted in the UK, the majority of respondents were supportive, provided that additional postgraduate education/training was undertaken [41] . In other studies, physicians were more cautious in their support, but acknowledged that a model of pharmacist prescribing for limited conditions, such as minor ailments, was a logical development [40, 50, 53, 75, 78] .
Other studies reported physicians' concern over: pharmacists' lack of clinical assessment and diagnosis skills, lack of access to individual patient medical records, legal considerations such as division of clinical responsibility of care, a potential negative effect on the physician-patient relationship, and issues concerning communication between the pharmacist prescriber and other members of the multidisciplinary team [42, 53, 82] . e. Nurses: Two UK studies reported the perspectives of nurses with respondents considering pharmacist prescribing for existing or new therapy very useful due to their knowledge in pharmacology and a belief that it will be clearer and safer [41, 43] . f. Policymakers: Government and pharmacy policymakers from the USA, Canada, and Nigeria anticipated benefit to pharmacist prescribing in terms of improved continuity of care, better patient outcomes, reduced prescribing costs, and reduced physician workload [39, 76, 78] . Concerns were, however, expressed by medical policymakers in relation to the need for additional training and access to individual patient medical records, without which there could be fragmented care [76] .
Postimplementation studies. a. General public: Two studies reported the perspectives of samples of the public, both exposed to pharmacist prescribing and not exposed to it, in the UK. Findings highlighted general support, particularly for the management of minor ailments and issuing repeat prescriptions. There were some concerns over pharmacists' training in diagnosis, lack of access to patients' medical records, and potential lack of privacy and confidentiality within a community pharmacy setting [28, 33] . b. Patients: Nine studies assessed the experience of patients who were exposed to pharmacist prescribing, while Hobson et al. included exposed and unexposed patients in the UK [64] and Feehan et al. had US patients who had never been exposed to pharmacist prescribing [72] .
Figure 2
Cumulative quality assessment of the 65 studies, grouped according to study design Table 3 Characteristics and key findings of included quantitative studies (n = 41) (continues)
Views and experiences of pharmacist prescribing: A systematic review Views and experiences of pharmacist prescribing: A systematic review Views and experiences of pharmacist prescribing: A systematic review Table 4 Characteristics and key findings of included qualitative studies (n = 21) Focus groups with pharmacists and face-to-face semistructured interviews with the mentors PP was perceived to reduce doctors' workload and improved continuity of care. IP was seen as contentious by mentors due to the diagnostic element.
(continues)
Views and experiences of pharmacist prescribing: A systematic review Table 4 (Continued) NMP: nonmedical prescribing; IP: independent prescribing; SP: supplementary prescribing; PP: pharmacist prescribing; GP, general practitioner Table 5 Characteristics and key findings of included mixed-methods studies (n = 3) Views and experiences of pharmacist prescribing: A systematic review
The majority of those patients who had consulted with a pharmacist prescriber were highly satisfied with the consultation overall, particularly the pharmacist's competence and capability, considering their prescribing to be as effective and safe as their physician. They also gave positive feedback relating to the pharmacist's personality, knowledge and communication skills as well as the consistency, accessibility, length and outcome of the care received [25, 27, 31, 34-36, 62, 64, 68, 71] .
In a recent study of prescribing by community pharmacists in the USA, patients who had yet to experience pharmacist prescribing were of the view that pharmacists should only dispense and provide medicines information other than a possible role in prescribing for minor conditions [72] .
c. Pharmacists: Twenty-four studies researched the perspectives of pharmacists postimplementation of prescribing rights mainly in the UK (n = 18], US [3] , and Canada [3] . The pharmacists sample in these studies included either prescribers [22, 26, 29, 35, 59, 62, 63, 65, 67, 69, 80] , nonprescribers [23, 24, 30, 32, 72, 73] or both [19, 20, 37, 58, 60, 66, 70] . Pharmacists positively perceived this expanded professional role and reported that drivers to undertake pharmacist prescribing include developing a clinical role, better patient management, personal development, enhancing job and patient satisfaction, improving self-confidence as well as reducing cost of therapy [19, 20, 22-24, 26, 29, 30, 32, 35, 37, 58-60, 62, 63, 65-67, 69, 70, 73, 80] .
Studies also concluded that implementing pharmacist prescribing was easier in secondary care compared to primary or community care due to logistics related to access to medical records and networking environment [29, 59, 65, 70, 80] .
Negative attitudes towards prescribing pharmacists were mainly related to increased liability, lack of time to engage in prescribing and lack of experience in diagnosis, in addition to medical resistance and difficulties in developing a CMP for every patient [19, 29, 30, 59, 60, 65, 66, 70] .
Due to liability and diagnosis-related issues, pharmacists preferred SP or prescribing for minor and chronic conditions [63, 66, 72] . However, other studies reported that SP was not believed to significantly save physicians' time or improve patient care due to the limited list of drugs they can prescribe under the CMP. Thus, IP will have a better impact [24, 29, 35, 62, 63, 65, 67] . d. Doctors: Seven studies explored doctors' perceptions of this new role for pharmacists, all of which were conducted in the UK. Of those, six studies reported the perspectives of doctors who had worked alongside pharmacist prescribers. The majority supported pharmacist prescribing across the studies with some benefits highlighted including more holistic and continuous patient care, better use of pharmacists' skills, effects of enhancing physicians' medicines knowledge, and drug cost saving [59, 61, 62, 65, 69] . While physicians reported reduced directpatient workload, the need to develop individual patient CMPs for SP was burdensome hence the impending implementation of IP was welcomed [35] .
The only study that investigated doctors who were not exposed to prescribing pharmacists reported that, with time, doctors are more likely to accept this new role [21] . e. Policymakers: Only one study from the USA explored the perceptions of policymakers involved in medical services coverage or formulary policies after the realisation of pharmacist prescribing. The main findings were that these decision-makers responded positively to pharmacist prescribing due to pharmacists' knowledge about drugs and their mechanisms of action [72] .
Facilitators of and barriers to pharmacist prescribing implementation
Many studies (n = 27, 42%) reported facilitators and barriers to the implementation of pharmacist prescribers as perceived by the different stakeholder groups [22-24, 26, 29, 37, 45, 46, 48, 50, 51, 56, 58-60, 62, 64, 65, 67, 69, 70, 72, 73, 77, 78, 80, 81] , which are summarized in Table 6 . The major facilitators to this role include pharmacist personal qualities (enthusiasm, communication skills, experience and training), practice setting (working in an interprofessional team), organizational, managerial and Table 6 Facilitators and barriers to pharmacist prescribing • Resources (workforce, access to medical records, space, time)
• Physicians and organizational support
• Funding
• Legal aspects (accountability, conflict of interest)
• Pharmacy practice recognition medical colleagues' support, as well as infrastructure and resources (number of pharmacist available, space and access to medical records) [22, 23, 58, 59, 67, 69, 70] . The main barriers reported are pharmacists' poor clinical skills if not prescribing collaboratively and issues relating to resources (access to medical records, shortage in pharmacy workforce, funding, time), support (doctors' opposition), logistics (accountability, conflict of interest, referral process) and poor recognition of pharmacy profession [22, 24, 26, 29, 45, 46, 48, 50, 51, 56, 58-60, 62, 64, 65, 69, 72, 73, 77, 78, 80, 81] .
Discussion
This systematic review summarizes the evidence around the views and experiences surrounding pharmacist prescribing from the perspectives of a diverse range of stakeholders in a range of countries and settings.
The majority of studies pre-and postimplementation reported positive views and experiences with main benefits described as: increased access to healthcare services, perceptions of enhanced patient outcomes, better use of pharmacists' skills and knowledge, improved job satisfaction, and reduced physician workload. However, concerns were noted over issues of: liability, limited pharmacist diagnosis skills, access to medical records, and lack of organizational and financial support. While review findings are derived from many studies of generally high methodological quality, there is a lack of mixed-methods approaches. These are being used increasingly within healthcare and allow both quantification of findings and in-depth exploration of key issues [83] .
Healthcare policies in countries such as the UK support the expansion of pharmacist prescribing and indeed there is a move to increase the number of pharmacists practicing within primary care practices [84] . The positive findings of this systematic review, together with previous reviews of effectiveness and safety [13, [85] [86] [87] [88] , provide evidence to support such developments. Furthermore, such review findings are important in those countries and settings starting to explore and develop models of pharmacist prescribing [2] . Interpretation and extrapolation of findings from studies conducted preimplementation are limited in that participants may not be fully aware of the aim, nature and scope of the intervention and may be influenced by experiences of similar or diverse interventions. This is apparent in terms of concerns over independent prescribing models in the UK and pharmacists' limited training in diagnosis. While this does allow assessment and prescribing of undiagnosed conditions, this must be within the prescribers' competence and indeed most pharmacist independent prescribers practise with patients in whom diagnosis has already been established by the doctor [6] . Concerns such as liability and skills that were voiced preimplementation were less common postimplementation as such studies allow participants to reflect on their real-life experiences. For example, doctors who had worked alongside pharmacist prescribers and patients managed by the pharmacists were very supportive of their professionalism and skills.
While lack of access to medical records is an issue, most notably within community pharmacy settings, this is being addressed within the UK with pharmacists having access to specific limited sections of the electronic medical record [89] . Many of the barriers and indeed facilitators can be explained by theories of implementation. It is therefore notable that only three of the 65 studies incorporated any mention of theory within the study design, conduct, and reporting [18, 58, 70] . There is a need for implementation studies to focus on theory to allow more systematic and comprehensive investigation of facilitators and barriers. Similarly, those planning implementation should include key theoretical elements at the outset to heighten the facilitators and lessen the barriers such as inadequate funding, access to resources, etc. The Consolidated Framework for Implementation Research (CFIR) is an integrative framework derived from many different theories. It is described in five domains: intervention characteristics; outer setting; inner setting; characteristics of the individuals involved; and the process of implementation [90] . All barriers identified postimplementation of pharmacist prescribing (e.g. funding, access issues etc.) would be eliminated in advance by using CFIR since it can serve as a guide for implementing an innovation. However, it is likely that these barriers reflected the stage of implementation and are likely to have been resolved over time.
Previous reviews have been limited in nature and rigour (thematic and scoping reviews], focused on preimplementation, lacked quality assessment of included studies, and focused on limited ranges of stakeholders in specific countries (UK and Canada) [88, 91, 92] . This systematic review was conducted according to best practices and is reported in accordance with the PRISMA Statement standards [93] . Furthermore, it was not limited to a specific country, setting, stakeholder group or implementation stage. However, the generalizability or transferability of findings to other countries or cultures may be limited, given that almost all studies were conducted postimplementation in the western world and mainly focused on pharmacists' perspectives. Moreover, several of these studies were conducted several years ago hence may no longer accurately reflect the current situation in those countries. While many implementation studies have been reported, it is still necessary to conduct such investigations in any country or setting planning to establish pharmacist prescribing to learn from the evidence-base. Future developments and studies should pay attention to theories of implementation and adopt mixed methods approaches with an inclusive range of stakeholders.
Conclusion
Many studies have reported stakeholders' views and experiences of pharmacist prescribing, preand postimplementation. While studies were from a limited number of countries, the overwhelming finding was positive, particularly in relation to increased access to healthcare services, perceptions of enhanced patients' outcomes, better use of pharmacists' skills and knowledge, improved job satisfaction, and reduced physicians' workload. Concerns were largely identified preimplementation and were related to organizational issues and perceived lack of pharmacists' diagnosis skills.
